ORCHPHARMA

Orchid Pharma Share Price

₹1,550.00 +5.6 (0.36%)

22 Jan, 2025 12:09

SIP TrendupStart SIP in ORCHPHARMA

Start SIP

Performance

  • Low
  • ₹1,506
  • High
  • ₹1,562
  • 52 Week Low
  • ₹703
  • 52 Week High
  • ₹1,997
  • Open Price₹1,554
  • Previous Close₹1,544
  • Volume204,284

Investment Returns

  • Over 1 Month -13.44%
  • Over 3 Month + 18.05%
  • Over 6 Month + 19.41%
  • Over 1 Year + 108.84%
SIP Lightning

Smart Investing Starts Here Start SIP with Orchid Pharma for Steady Growth!

Invest Now

Orchid Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 66.1
  • PEG Ratio
  • 2.8
  • Market Cap Cr
  • 7,862
  • P/B Ratio
  • 6.4
  • Average True Range
  • 82.85
  • EPS
  • 23.46
  • Dividend Yield
  • 0
  • MACD Signal
  • 9.15
  • RSI
  • 34.75
  • MFI
  • 41.8

Orchid Pharma Financials

Orchid Pharma Technicals

EMA & SMA

Current Price
₹1,550.00
+ 5.6 (0.36%)
pointer
  • stock-down_img
  • Bearish Moving Average 12
  • stock-up_img
  • Bullish Moving Average 4
  • 20 Day
  • ₹1,717.60
  • 50 Day
  • ₹1,674.27
  • 100 Day
  • ₹1,563.95
  • 200 Day
  • ₹1,380.44

Resistance and Support

1583.67 Pivot Speed
  • R3 1,764.13
  • R2 1,717.07
  • R1 1,630.73
  • S1 1,497.33
  • S2 1,450.27
  • S3 1,363.93

What's your outlook on Orchid Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Orchid Pharma is a leading pharmaceutical company in India, specializing in the manufacture of active pharmaceutical ingredients (APIs) and generic formulations. It serves global markets with a focus on antibiotics, anti-inflammatory, and central nervous system therapies.

Orchid Pharma has an operating revenue of Rs. 904.80 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 11% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 27% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Orchid Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-23 Audited Results
2024-02-08 Quarterly Results
2023-11-04 Quarterly Results

Orchid Pharma F&O

Orchid Pharma Shareholding Pattern

69.84%
16.78%
0.81%
1.94%
0.12%
7.59%
2.92%

About Orchid Pharma

  • NSE Symbol
  • ORCHPHARMA
  • BSE Symbol
  • 524372
  • Managing Director
  • Mr. Manish Dhanuka
  • ISIN
  • INE191A01027

Similar Stocks to Orchid Pharma

Orchid Pharma FAQs

Orchid Pharma share price is ₹1,550 As on 22 January, 2025 | 11:55

The Market Cap of Orchid Pharma is ₹7861.5 Cr As on 22 January, 2025 | 11:55

The P/E ratio of Orchid Pharma is 66.1 As on 22 January, 2025 | 11:55

The PB ratio of Orchid Pharma is 6.4 As on 22 January, 2025 | 11:55

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23